Biogen Inc vs Danaos Corporation — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Danaos Corporation trades at $135.01 (market cap $2.46B). The key difference: Biogen Inc is far larger — about 12.2× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DAC | |
|---|---|---|
Market Cap | $30.13B | $2.46B |
Sector | Health | Technology |
52-Week High | $216.63 | $143.15 |
52-Week Low | $128.93 | $84.05 |
Enterprise Value | $37.20B | $2.44B |
Dividend Yield | — | 2.67% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →